Pharmaceutical industry – Page 10
-
Business
US grants Pfizer’s Covid-19 vaccine full approval
WHO calls for delay to booster programmes to allow more global distribution
-
Business
The multi-pronged search for Covid-19 treatments
Drugs that block infection or reduce inflammation will complement vaccine protection
-
Opinion
The price of failure
Drug market structures and high R&D failure rates can tempt companies into bad pricing behaviour
-
Business
Budget cuts at UK medicines regulator raise eyebrows
MHRA to cut 300 jobs amid financial pressures arising from Brexit
-
Business
Brewing up plant-inspired medicines
Antheia reconstructs complex biochemical pathways in yeasts to speed up production of natural product-based drugs
-
Webinar
Find robust operating points using JMP’s Simulation Experiment tool
Learn how simulations can be used to minimise defect rate and improve crucial targets
-
Business
Developing countries sidelined in Covid-19 vaccine scramble
Lack of funds and local manufacturing capacity has prevented Covax from competing with wealthier nations’ self-interest
-
Article
People, partnerships, pharma: exploring the science of innovation
The importance of fostering collaborative cultures to accelerate innovation
-
Article
Peptones: over 100 years of life-saving innovation
After a century, peptones continue to play a vital role in biopharmaceutical innovation
-
Business
Pfizer backs protein degrader drugs with Arvinas deal
$1bn investment to commercialise breast cancer treatment
-
Webinar
The era of data analytics: What it takes to succeed beyond the hype
Find out how to make better decisions about your data using analytics and subject matter knowledge
-
Opinion
Putting combustion into reverse
Unburning carbon dioxide economically and at scale is a tough problem, but potentially world-changing
-
Business
Industry tightens emissions reduction targets
As COP26 approaches, many firms are announcing ambitious climate goals. But are they achievable?
-
Opinion
Kathleen Culhane Lathbury – an industrial pioneer
Nina Notman tells the story of the interwar industrial chemist whose analytical skill and persistence saw her outmanoeuvre sexism and prove her research aptitude
-
Opinion
Opening up a cellular black box
Working out how biomolecular condensates work may reveal a lot about the success or failure of different drugs
-
Business
Sartan contaminant recall hits generics manufacturers
Three European suppliers recalling multiple batches of medicines owing to active ingredient contamination
-
Business
US judge rules against GSK in trade secrets dispute
Firm will not receive compensation for claimed loses of over $1bn from theft of confidential information by two former scientists
-
Business
BMS and Eisai agree antibody-drug conjugate commercialisation deal
Companies will jointly develop cancer treatment, with BMS paying up to $3 billion for shared rights
-
Business
Regeneron’s Covid-19 antibodies help those who can’t make their own
Regn-Cov2 reduces deaths and shortens hospitalisation for these patients, even when given at late stages of infection
-
Business
Alzheimer’s antibody gets surprise US approval
Good news for industry and future drug approvals, but physicians doubt it will be effective for most patients